StockWatch
·
Biotechnology: Pharmaceutical Preparations
RegulatoryApr 30, 2026, 04:27 PM

BGM Receives Nasdaq Minimum Bid Price Deficiency Notice

AI Summary

BGM Group Ltd. received a deficiency letter from Nasdaq on April 24, 2026, notifying the company that it is not in compliance with Nasdaq Rule 5550(a)(2) due to its Class A ordinary shares trading below $1.00 for 30 consecutive business days. The company has 180 calendar days, until October 21, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. BGM is monitoring its share price and evaluating options, including a reverse stock split, to address the deficiency and avoid potential delisting.

Key Highlights

  • BGM received a deficiency letter from Nasdaq for not meeting the minimum $1.00 bid price requirement.
  • The company's Class A ordinary shares traded below $1.00 for 30 consecutive business days.
  • BGM has 180 calendar days, until October 21, 2026, to regain compliance.
  • To comply, the closing bid price must be at least $1.00 for 10 consecutive business days.
  • The company is evaluating options, including a reverse stock split, to regain compliance.
  • Failure to comply by the deadline could lead to delisting from Nasdaq.